CNX Therapeutics is a rapidly growing European pharmaceutical company dedicated to improving the lives of patients through the supply of essential medicines. We license and distribute a portfolio of medicines for CNS, critical care and other conditions, both directly and through strategic partnerships, in over 60 countries worldwide.

A certified B Corp company, our vision is to become a recognised partner of choice through our commercial excellence, patient focus and presence across Europe.